JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB181114

Anti-CPT2 antibody [EPR13626] - C-terminal

2

(1 Review)

|

(38 Publications)

Rabbit Recombinant Monoclonal CPT2 antibody. C-terminal. Suitable for WB, ICC/IF, IHC-P and reacts with Mouse, Rat, Human samples. Cited in 38 publications.

View Alternative Names

CPT1, CPT2, Carnitine palmitoyltransferase II, CPT II

12 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)

Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling CPT2 with unpurified ab181114 at 1/100 dilution, followed by prediluted HRP Polymer for Rabbit IgG. Counter stained with Hematoxylin.

Immunocytochemistry/ Immunofluorescence - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)

Immunofluorescent analysis of 4% paraformaldehyde-fixed MCF7 cells labeling CPT2 with unpurified ab181114 at 1/100 dilution, followed by Goat anti rabbit IgG (Alexa Fluor® 488) secondary antibody at 1/200 dilution. Counter stained with Dapi.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)

Immunohistochemical analysis of paraffin-embedded Human skeletal muscle tissue labeling CPT2 with unpurified ab181114 at 1/100 dilution, followed by prediluted HRP Polymer for Rabbit IgG. Counter stained with Hematoxylin.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)

Immunohistochemical analysis of paraffin embedded human liver carcinoma tissue section labelling CPT2 with purified ab181114 at dilution of 1/50. The secondary antibody used was Goat Anti-Rabbit IgG H&L (HRP) (ab97051), at a dilution of 1/500. The sample was counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control and is shown in the inset.

Immunocytochemistry/ Immunofluorescence - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)

Immunocytochemistry/Immunofluorescence analysis of MCF-7 (human breast carcinoma) cells labelling CPT2 with purified ab181114 at 1/100. Cells were fixed with 100% methanol and permeabilized with 0.1% Triton X-100. ab150077, Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. The cells were co-stained with ab7291, a mouse anti-tubulin antibody (1/1000) using ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/1000) as the secondary. Nuclei couterstained with DAPI (blue).

For negative control 1, rabbit primary antibody was used, followed by anti-mouse secondary antibody (ab150120). For negative control 2, mouse primary antibody (ab7291) was used followed by anti-rabbit secondary antibody (ab150077).

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)

Immunohistochemical analysis of paraffin embedded rat colon tissue section labelling CPT2 with purified ab181114 at dilution of 1/50. The secondary antibody used was HRP-conjugated Goat Anti-Rabbit IgG H&L (ab97051) at dilution of 1/500. The sample was counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control and is shown in the inset.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)

Immunohistochemical analysis of paraffin embedded mouse kidney tissue section labelling CPT2 with purified ab181114 at dilution of 1/50. The secondary antibody used was HRP-conjugated Goat Anti-Rabbit IgG H&L (ab97051) at dilution of 1/500. The sample was counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control and is shown in the inset.

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)
  • WB

Lab

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)

Lanes 1 - 4 : Merged signal (red and green). Green - ab181114 observed at 70 kDa. Red - loading control, ab8245, observed at 37 kDa.

ab181114 was shown to specifically react with CPT2 in wild-type HAP1 cells. No band was observed when CPT2 knockout samples were examined. Wild-type and CPT2 knockout samples were subjected to SDS-PAGE. ab181114 and ab8245 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/10,000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed ab216776 secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (ab181114) at 1/1000 dilution

Lane 1:

Wild-type HAP1 whole cell lysate at 20 µg

Lane 2:

CPT2 knockout HAP1 whole cell lysate at 20 µg

Lane 3:

HeLa whole cell lysate at 20 µg

Lane 4:

MCF7 whole cell lysate at 20 µg

Predicted band size: 74 kDa

false

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)
  • WB

Lab

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)

Lanes 1- 2 : Merged signal (red and green). Green - ab181114 observed at 74 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (ab8245) observed at 37 kDa.

ab181114 was shown to react with CPT2/CPT1 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab265931 (knockout cell lysate ab257180) was used. Wild-type HeLa and CPT2 knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab181114 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (ab181114) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

CPT2 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human CPT2 knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-cpt2-knockout-hela-cell-line-ab265931'>ab265931</a>)

Predicted band size: 74 kDa

Observed band size: 74 kDa

false

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)
  • WB

Unknown

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)

Blocking and diluting buffer 5% NFDM/TBST

All lanes:

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (ab181114) at 1/2000 dilution

Lane 1:

Human fetal kidney tissue lysate at 20 µg

Lane 2:

MCF-7 (human breast carcinoma) whole cell lysate at 20 µg

Lane 3:

Mouse heart tissue lysate at 20 µg

Lane 4:

Mouse kidney tissue lysate at 20 µg

Secondary

All lanes:

Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/2000 dilution

Predicted band size: 74 kDa

Observed band size: 67 kDa

false

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)
  • WB

Unknown

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)

Blocking and diluting buffer 5% NFDM/TBST

All lanes:

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (ab181114) at 1/1000 dilution

Lane 1:

Rat kidney tissue lysate at 20 µg

Lane 2:

Rat liver tissue lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 74 kDa

Observed band size: 67 kDa

false

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)
  • WB

Supplier Data

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (AB181114)

All lanes:

Western blot - Anti-CPT2 antibody [EPR13626] - C-terminal (ab181114) at 1/10000 dilution

Lane 1:

Human fetal liver tissue lysate at 20 µg

Lane 2:

Human fetal kidney tissue lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab136636'>ab136636</a>) at 1/500 dilution

Predicted band size: 74 kDa

Observed band size: 67 kDa

false

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-CPT2 antibody [EPR13626] - C-terminal

  • Carrier free

    Anti-CPT2 antibody [EPR13626] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR13626

Isotype

IgG

Carrier free

No

Reacts with

Mouse, Rat, Human

Applications

ICC/IF, WB, IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/50 - 1/100", "ICCIF-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/50 - 1/100", "IHCP-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/50 - 1/100", "IHCP-species-notes": "<p></p>" }, "Rat": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/50 - 1/100", "IHCP-species-notes": "<p></p>" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Carnitine palmitoyltransferase 2 (CPT2) also known as CPT-2 is an enzyme located mainly in the mitochondria of liver muscle and heart tissues. This enzyme has a molecular mass of approximately 68 kDa. CPT2 plays a mechanical role in the transfer of long-chain fatty acids from the cytosol into the mitochondrial matrix completing the process initiated by CPT1 on the outer mitochondrial membrane. CPT2 acts on the inner mitochondrial membrane converting acylcarnitine back into acyl-CoA which is an essential step in beta-oxidation. Expression of CPT2 is higher in tissues with elevated fatty acid oxidation rates.
Biological function summary

CPT2 is integral to the mitochondrial pathway of fatty acid metabolism. It functions as part of the carnitine shuttle system a complex important for the conversion of acylcarnitine to acyl-CoA inside the mitochondria. This role is vital for the full oxidation of long-chain fatty acids. Through its action CPT2 aids in maintaining energy homeostasis and producing ketone bodies especially during periods of fasting or strenuous exercise.

Pathways

CPT2 is involved in both the beta-oxidation and the carnitine shuttle pathways. These pathways facilitate the energy production from fatty acids particularly during states of low carbohydrate availability. CPT2 works closely with CPT1 as both enzymes form the gateway for the entry of long-chain fatty acids into mitochondria. Together with enzymes from the tricarboxylic acid cycle CPT2 helps sustain ATP production under such metabolic conditions.

Defects in CPT2 can lead to disorders like CPT2 deficiency which present with symptoms of muscle weakness and recurrent rhabdomyolysis especially during prolonged fasting or significant exercise. This deficiency can also result in hypoketotic hypoglycemia and liver dysfunction. CPT2-related disorders often involve altered interactions with proteins such as the acyl-CoA dehydrogenases impacting the normal fatty acid oxidation process and causing metabolic disturbances.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Involved in the intramitochondrial synthesis of acylcarnitines from accumulated acyl-CoA metabolites (PubMed : 20538056, PubMed : 24780397). Reconverts acylcarnitines back into the respective acyl-CoA esters that can then undergo beta-oxidation, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion. Active with medium (C8-C12) and long-chain (C14-C18) acyl-CoA esters (PubMed : 20538056).
See full target information CPT2

Publications (38)

Recent publications for all applications. Explore the full list and refine your search

Redox biology 86:103808 PubMed40774144

2025

Age-related declines in mitochondrial Prdx6 contribute to dysregulated muscle bioenergetics.

Applications

Unspecified application

Species

Unspecified reactive species

Jose Adan Arevalo,Dianna Xing,Roberto Garcia Leija,Max A Thorwald,Diana Daniela Moreno-Santillán,Kaitlin N Allen,Giovanna Selleghin-Veiga,Heidi C Avalos,Eva Utke,Justin L Conner,George A Brooks,José Pablo Vázquez-Medina

Nature metabolism 7:1392-1403 PubMed40595405

2025

Triglycerides are an important fuel reserve for synapse function in the brain.

Applications

Unspecified application

Species

Unspecified reactive species

Mukesh Kumar,Yumei Wu,Justin Knapp,Catherine L Pontius,Daehun Park,Rose E Witte,Rachel McAllister,Kallol Gupta,Kartik N Rajagopalan,Pietro De Camilli,Timothy A Ryan

Nature communications 16:5465 PubMed40593619

2025

Mitophagy mitigates mitochondrial fatty acid β-oxidation deficient cardiomyopathy.

Applications

Unspecified application

Species

Unspecified reactive species

Nuo Sun,Hayley Barta,Samhita Chaudhuri,Kangxuan Chen,Jiacheng Jin,Hongke Luo,Mingchong Yang,Judith Krigman,Ruohan Zhang,Shridhar Sanghvi,Shiori Sekine,Hannah Sanders,Dominic Kolonay,Mudra Patel,Kedryn Baskin,Harpreet Singh,Pengyi Zhang,Gang Xin,Toren Finkel

JCI insight 10: PubMed40402578

2025

Involvement of impaired carnitine-induced fatty acid oxidation in experimental and human diabetic kidney disease.

Applications

Unspecified application

Species

Unspecified reactive species

Sakuya Ito,Kensei Taguchi,Goh Kodama,Saori Kubo,Tomofumi Moriyama,Yuya Yamashita,Yunosuke Yokota,Yosuke Nakayama,Yusuke Kaida,Masami Shinohara,Kyoko Tashiro,Keisuke Ohta,Sho-Ichi Yamagishi,Kei Fukami

Cell death discovery 11:193 PubMed40268915

2025

High-fat diet promotes lipotoxicity in the podocytes of uninephrectomized mice: a targeted lipidomics and kidney podocyte-specific analysis.

Applications

Unspecified application

Species

Unspecified reactive species

Se-Hyun Oh,You-Jin Kim,Subin Bae,Hee-Yeon Jung,So-Young Park,Jeong-Hoon Lim,Jang-Hee Cho,Chan-Duck Kim,Sun-Hee Park,Tae-Hwan Kwon,Yong-Jin Kim,Kwang-Hyeon Liu,Yong-Lim Kim

Cell death & disease 16:308 PubMed40240362

2025

IGF2BP3/ESM1/KLF10/BECN1 positive feedback loop: a novel therapeutic target in ovarian cancer via lipid metabolism reprogramming.

Applications

Unspecified application

Species

Unspecified reactive species

Anbo Gao,Juan Zou,Tian Zeng,Mei Qin,Xing Tang,Ting Yi,Guangming Song,Jie Zhong,Yuhuan Zeng,Wenchao Zhou,Qin Gao,Qunfeng Zhang,Juan Zhang,Yukun Li

World journal of gastroenterology 30:5055-5069 PubMed39713165

2024

Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease liver cancer stem cell activation.

Applications

Unspecified application

Species

Unspecified reactive species

Ling-Ling Wang,Yu-Ming Lu,Yi-Han Wang,Yi-Fan Wang,Rong-Fei Fang,Wen-Li Sai,Deng-Fu Yao,Min Yao

Cell death & disease 15:674 PubMed39277582

2024

Impaired SUMOylation of FoxA1 promotes nonalcoholic fatty liver disease through down-regulation of Sirt6.

Applications

Unspecified application

Species

Unspecified reactive species

Dongmei Zou,Jinwen Liao,Min Xiao,Liang Liu,Dongling Dai,Mingguo Xu

Food science & nutrition 12:5052-5064 PubMed39055214

2024

Mulberry and -based solid beverage attenuate hyperlipidemia and hepatic steatosis via adipose tissue-liver axis.

Applications

Unspecified application

Species

Unspecified reactive species

An-Qi Zhu,Nin Luo,Ling-Yue Sun,Xiao-Ting Zhou,Shi-Sheng Chen,Zebo Huang,Xin-Liang Mao,Kun-Ping Li

Gut microbes 16:2323227 PubMed38436067

2024

Gut microbiota-palmitoleic acid-interleukin-5 axis orchestrates benzene-induced hematopoietic toxicity.

Applications

Unspecified application

Species

Unspecified reactive species

Lei Zhang,Ziyan Liu,Wei Zhang,Jingyu Wang,Huiwen Kang,Jiaru Jing,Lin Han,Ai Gao
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com